We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
+47.82%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$477M
AUM Growth
+$186M
Cap. Flow
-$39.3M
Cap. Flow %
-8.24%
Top 10 Hldgs %
100%
Holding
6
New
Increased
Reduced
3
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$36.4M
2
ALKS icon
Alkermes
ALKS
+$1.86M
3
CLDX icon
Celldex Therapeutics
CLDX
+$993K

Sector Composition

Rank Sector Weight
1 Healthcare 96.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$305M 63.94%
12,841,798
-1,572,075
-11% -$36.4M
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$138M 28.84%
2,679,835
ALKS icon
3
Alkermes
ALKS
$8.82B
$14.6M 3.05%
750,000
-114,417
-13% -$1.86M
INDA icon
4
iShares MSCI India ETF
INDA
$6.71B
$9.29M 1.95%
320,000
EPI icon
5
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$8.01M 1.68%
400,000
CLDX icon
6
Celldex Therapeutics
CLDX
$2.77B
$2.56M 0.54%
196,846
-224,000
-53% -$993K

Similar funds

Meditor Group's Q2 2020 Portfolio in Review

As of Q2 2020, Meditor Group held 6 positions worth $477M, up 64% from $290M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Meditor Group withdrew a net $39.3M in Q2 2020, reducing 3 holdings. Its largest reduction was Exelixis, cutting an estimated $36.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier.

  • Meditor Group's biggest Q2 2020 reduction was Exelixis, cutting an estimated $36.4M.
  • Meditor Group's ten largest holdings make up 100% of its $477M portfolio in Q2 2020.
  • Meditor Group opened 0 new positions and closed 0 in Q2 2020.
  • Meditor Group's portfolio value rose 64% quarter-over-quarter to $477M.

Based on Meditor Group's 13F filing for Q2 2020, filed 14 Jul 2020.